Loading...
•
Dec 31, 2019
Bioxcel Therapeutics Q4 2019 Earnings Report
Reported a net loss, increased research and development expenses, and general and administrative expenses compared to the same period in 2018.
Key Takeaways
BioXcel Therapeutics reported a net loss of $8.3 million for the fourth quarter of 2019, compared to a net loss of $7.1 million for the same period in 2018. Research and development expenses were $6.5 million, and general and administrative expenses were $1.9 million.
Key BXCL501 data readouts are expected in mid-2020, including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia.
The balance sheet was strengthened through a follow-on offering, raising $60 million in net proceeds.
Significant growth was achieved in the BXCL501 and BXCL701 programs.
A fourth indication for BXCL501 was announced, expanding its potential therapeutic use.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...